

R^7 is H; R^{10} is H;
 R^8 is H, halogen, $-OR^a$, $-NR^cR^d$, $-C(O)R^a$, $-C(O)NR^cR^d$, G^2 , $-(C_1-C_6 \text{ alkylenyl})-G^2$,
 or $-(C_1-C_6 \text{ alkylenyl})-NR^cR^d$;
 R^9 is H, halogen, $-CN$, C_1-C_6 haloalkyl, $-N(R^e)S(O)_2R^b$, $-S(O)_2R^a$, $-S(O)_2NR^cR^d$, $-(C_1-C_6 \text{ alkylenyl})-G^2$ wherein G^2 is optionally substituted heterocycle, $-(C_1-C_6 \text{ alkylenyl})-S(O)_2R^a$, $-(C_1-C_6 \text{ alkylenyl})-S(O)_2NR^cR^d$, $-(C_1-C_6 \text{ alkylenyl})-NR^cR^d$, or $-(C_1-C_6 \text{ alkylenyl})-N(R^e)S(O)_2R^b$;
 R^a , R^c , R^d , and R^e , at each occurrence, are each independently H, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 haloalkyl, G^2 , or C_1-C_6 alkyl wherein the C_1-C_6 alkyl is optionally substituted with one substituent selected from the group consisting of $-OR^{y1}$, $-NR^{y3}R^{y4}$, $-C(O)OR^{y1}$, $-C(O)NR^{y3}R^{y4}$, $-S(O)_2R^{y1}$, $-S(O)_2NR^{y3}R^{y4}$, and G^2 ;
 R^b , at each occurrence, is independently C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 haloalkyl, G^2 , or C_1-C_6 alkyl wherein the C_1-C_6 alkyl is optionally substituted with one substituent selected from the group consisting of $-OR^{y1}$, $-NR^{y3}R^{y4}$, $-C(O)OR^{y1}$, $-C(O)NR^{y3}R^{y4}$, $-S(O)_2R^{y1}$, $-S(O)_2NR^{y3}R^{y4}$, and G^2 ;
 G^2 , at each occurrence, are each independently aryl, heteroaryl, heterocycle, cycloalkyl, or cycloalkenyl; and each G^2 group is optionally substituted with 1, 2, 3, 4, or 5 R^{2g} groups;
 R^{2g} , at each occurrence, is independently C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, halogen, C_1-C_6 haloalkyl, $-CN$, NO_2 , $-OR^{y1}$, $-OC(O)R^{y2}$, $-OC(O)NR^{y3}R^{y4}$, $-SR^{y1}$, $-S(O)_2R^{y1}$, $-S(O)_2NR^{y3}R^{y4}$, $-C(O)R^{y1}$, $-C(O)OR^{y1}$, $-C(O)NR^{y3}R^{y4}$, $-NR^{y3}R^{y4}$, $-N(R^{y3})C(O)R^{y2}$, $-N(R^{y3})S(O)_2R^{y2}$, $-N(R^{y3})C(O)O(R^{y2})$, $-N(R^{y3})C(O)NR^{y3}R^{y4}$, $-N(R^{y3})S(O)_2NR^{y3}R^{y4}$, G^{2b} , $-(C_1-C_6 \text{ alkylenyl})-OR^{y1}$, $-(C_1-C_6 \text{ alkylenyl})-OC(O)R^{y2}$, $-(C_1-C_6 \text{ alkylenyl})-OC(O)NR^{y3}R^{y4}$, $-(C_1-C_6 \text{ alkylenyl})-S(O)_2R^{y1}$, $-(C_1-C_6 \text{ alkylenyl})-S(O)_2NR^{y3}R^{y4}$, $-(C_1-C_6 \text{ alkylenyl})-C(O)R^{y1}$, $-(C_1-C_6 \text{ alkylenyl})-C(O)OR^{y1}$, $-(C_1-C_6 \text{ alkylenyl})-C(O)NR^{y3}R^{y4}$, $-(C_1-C_6 \text{ alkylenyl})-NR^{y3}R^{y4}$, $-(C_1-C_6 \text{ alkylenyl})-N(R^{y3})C(O)R^{y2}$, $-(C_1-C_6 \text{ alkylenyl})-N(R^{y3})S(O)_2R^{y2}$, $-(C_1-C_6 \text{ alkylenyl})-N(R^{y3})C(O)O(R^{y2})$, $-(C_1-C_6 \text{ alkylenyl})-N(R^{y3})C(O)NR^{y3}R^{y4}$, $-(C_1-C_6 \text{ alkylenyl})-N(R^{y3})S(O)_2NR^{y3}R^{y4}$, $-(C_1-C_6 \text{ alkylenyl})-CN$, or $-(C_1-C_6 \text{ alkylenyl})-G^{2b}$;

3-{2-(2,4-difluorophenoxy)-5-[(morpholin-4-ylsulfonyl)methyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-5-ethyl-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

5-chloro-3-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

1-[4-(2,4-difluorophenoxy)-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]-N-methylmethanesulfonamide;

N-{4-[(4,4-difluorocyclohexyl)oxy]-3-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl}ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-2-fluoro-5-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)phenyl]methanesulfonamide;

3-{2-[(2,4-difluorophenyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one;

3-{2-[(4,4-difluorocyclohexyl)oxy]-5-(methylsulfonyl)phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one; and

3-{2-[(cyclopropylmethyl)amino]-5-[(methylsulfonyl)methyl]phenyl}-1-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one.

25. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

26. Use of a therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer in a subject.

27. The use of claim 26 wherein the cancer is selected from the group consisting of: acoustic neuroma, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute t-cell leukemia, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chondrosarcoma, chordoma,